DavidWRussellMD

PubMed

• Does race make a difference in how long men with advanced prostate cancer live when treated with abiraterone or enzalutamide?
  Daniel J George, Krishnan Ramaswamy, Ahong Huang, David Russell, Neil M Schultz, Nora Janjan, Stephen J Freedland> ;Future Oncology. 2022 Oct 13
• 20 citations
  Enzalutamide Monotherapy vs Active Surveillance in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial.
  Neal D Shore, Joseph Renzulli, Neil E Fleshner, Courtney M P Hollowell, Srinivas Vourganti, Jonathan Silberstein, Rizwan Siddiqui, John Hairston, Dina Elsouda, David R...> ;JAMA Oncology. 2022 Aug 1
• 10 citations
  Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER.
  Anthony M Joshua, Andrew Armstrong, Megan Crumbaker, Howard I Scher, Johann de Bono, Bertrand Tombal, Maha Hussain, Cora N Sternberg, Silke Gillessen, Joan Carles, Kar...> ;European Journal of Cancer. 2022 Jul 1
• 13 citations
  Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer
  Daniel J. George, Krishnan Ramaswamy, Ahong Huang, David Russell, Jack Mardekian, Neil M. Schultz, Nora Janjan, Stephen J. Freedland> ;Prostate Cancer and Prostatic Diseases. 2021 Nov 3
• 3 citations
  N-Acetylcysteine prevents amyloid-β secretion in neurons derived from human pluripotent stem cells with trisomy 21.
  Hiromitsu Toshikawa, Akihiro Ikenaka, Li B. Li, Yoko Nishinaka-Arai, Akira Niwa, Akira Ashida, Yasuhiro Kazuki, Tatsutoshi Nakahata, Hiroshi Tamai, David W. Russell, M...> ;Scientific Reports. 2021 Aug 30
• 8 citations
  Therapeutic discovery for marrow failure with MDS predisposition using pluripotent stem cells
  Melisa Ruiz-Gutierrez, Özge Vargel Bölükbaşı, Gabriela Alexe, Adriana G Kotini, Kaitlyn Ballotti, Cailin E. Joyce, David W. Russell, Kimberly Stegmaier, Kasiani C. Mye...> ;JCI Insight. 2019 Jun 20
• 9 citations
  Foamy Virus Vector Carries a Strong Insulator in Its Long Terminal Repeat Which Reduces Its Genotoxic Potential.
  Michael A. Goodman, Paritha Arumugam, Devin Pillis, Anastacia Loberg, Mohammed Nasimuzzaman, Danielle Lynn, Johannes Christiaan Maria van der Loo, Phillip J. Dexheimer...> ;Journal of Virology. 2018 Jan 1
• Identification of liver-specific enhancer-promoter activity in the 3' untranslated region of the wild-type AAV2 genome.
  Logan, G. J.,Dane, A. P.,Hallwirth, C. V.,Smyth, C. M.,Wilkie, E. E.,Amaya, A. K.,Zhu, E.,Khandekar, N.,Ginn, S. L.,Liao, SHY.,Cunningham, S. C.,Sasaki, N.,Cabanes-Cre...> ;Nat. Genet.. 2017 Jun 20
• 11 citations
  Production and purification of high-titer foamy virus vector for the treatment of leukocyte adhesion deficiency.
  Nasimuzzaman, Danielle Lynn, Rebecca Ernst, Michele Beuerlein, Richard H. Smith, Archana Shrestha, Scott Cross, Kevin A. Link, Carolyn Lutzko, Diana Nordling, David W....> ;Molecular Therapy. Methods & Clinical Development. 2016 Jan 1
• 59 citations
  Interdependence between Interleukin-1 and Tumor Necrosis Factor Regulates TNF-Dependent Control of Mycobacterium tuberculosis Infection.
  Nelson C. Di Paolo, Shahin Shafiani, Tracey A. Day, Thalia Papayannopoulou, David W. Russell, Yoichiro Iwakura, David R. Sherman, Kevin B. Urdahl, Dmitry M. Shayakhmetov> ;Immunity. 2015 Dec 15
• A genome-wide map of adeno-associated virus-mediated human gene targeting.
  Deyle, D. R.,Hansen, R. S.,Cornea, A. M.,Li, L. B.,Burt, A. A.,Alexander, I. E.,Sandstrom, R. S.,Stamatoyannopoulos, J. A.,Wei, C. L.,Russell, D. W.> ;Nat. Struct. Mol. Biol.. 2014 Oct 06
• The effects of polymorphisms on human gene targeting.
  Deyle, D. R.,Li, L. B.,Ren, G.,Russell, D. W.> ;Nucleic Acids Res.. 2013 Dec 29
• Analysis of inflammatory and lipid metabolic networks across RAW264.7 and thioglycolate-elicited macrophages.
  Maurya MR, Gupta S, Li X, Fahy E, Dinasarapu AR, Sud M, Brown HA, Glass CK, Murphy RC, Russell DW, Dennis EA, Subramaniam S> ;J. Lipid Res.. 2013-09-01
• Lack of genotoxicity due to foamy virus vector integration in human iPSCs.
  Deyle, D. R.,Khan, I. F.,Ren, G.,Russell, D. W.> ;Gene Ther.. 2013 Aug
• Genetic Defects in Bile Acid Conjugation Cause Fat-Soluble Vitamin Deficiency
  Philip Rosenthal, Kevin E Bove, Carol Potter, David W Russell, Alan F Hofmann, James E Heubi, Joel E Lavine> ;Gastroenterology. 2013 May
• Normal collagen and bone production by gene-targeted human osteogenesis imperfecta iPSCs.
  Deyle DR, Khan IF, Ren G, Wang P, Kho J, Schwarze U, Russell DW> ;Mol. Ther.. 2012-01-01
• Nonintegrating foamy virus vectors.
  Deyle DR, Li Y, Olson EM, Russell DW> ;J. Virol.. 2010-09-01
• Gene targeting of mutant COL1A2 alleles in mesenchymal stem cells from individuals with osteogenesis imperfecta.
  Chamberlain JR, Deyle DR, Schwarze U, Wang P, Hirata RK, Li Y, Byers PH, Russell DW> ;Mol. Ther.. 2008-01-01
• Analysis of HSD3B7 knockout mice reveals that a 3alpha-hydroxyl stereochemistry is required for bile acid function.
  Shea HC, Head DD, Setchell KDR, Russell DW> ;Proc. Natl. Acad. Sci. U.S.A.. 2007-07-10
• Cloning of the human cholesterol 7 alpha-hydroxylase gene (CYP7) and localization to chromosome 8q11-q12.
  Cohen JC, Cali JJ, Jelinek DF, Mehrabian M, Sparkes RS, Lusis AJ, Russell DW, Hobbs HH> ;Genomics. 1992-09-01
• Multiple crm- mutations in familial hypercholesterolemia. Evidence for 13 alleles, including four deletions.
  Hobbs HH, Leitersdorf E, Goldstein JL, Brown MS, Russell DW> ;J. Clin. Invest.. 1988-03-01
• Deletion of exon encoding cysteine-rich repeat of low density lipoprotein receptor alters its binding specificity in a subject with familial hypercholesterolemia.
  Hobbs HH, Brown MS, Goldstein JL, Russell DW> ;J. Biol. Chem.. 1986-10-05
• The LDL receptor in familial hypercholesterolemia: use of human mutations to dissect a membrane protein.
  Russell DW, Lehrman MA, Südhof TC, Yamamoto T, Davis CG, Hobbs HH, Brown MS, Goldstein JL> ;Cold Spring Harb. Symp. Quant. Biol.. 1986-01-01
• Join now to see all